GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Inventory-to-Revenue

Verici Dx (Verici Dx) Inventory-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Verici Dx's Average Total Inventories for the quarter that ended in Jun. 2023 was $0.00 Mil. Verici Dx's Revenue for the six months ended in Jun. 2023 was $0.02 Mil. Verici Dx's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.00.

Verici Dx's Inventory-to-Revenue for the quarter that ended in Jun. 2023 stayed the same from Dec. 2022 (0.00) to Dec. 2022 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Verici Dx's Days Inventory for the six months ended in Jun. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.


Verici Dx Inventory-to-Revenue Historical Data

The historical data trend for Verici Dx's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Inventory-to-Revenue Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22
Inventory-to-Revenue
- - -

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23
Inventory-to-Revenue - - - - -

Competitive Comparison of Verici Dx's Inventory-to-Revenue

For the Diagnostics & Research subindustry, Verici Dx's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's Inventory-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Verici Dx's Inventory-to-Revenue falls into.



Verici Dx Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Verici Dx's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Inventory-to-Revenue (A: Dec. 2022 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2021 ) + Total Inventories (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=N/A

Verici Dx's Inventory-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue (Q: Jun. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2022 ) + Total Inventories (Q: Jun. 2023 )) / count ) / Revenue (Q: Jun. 2023 )
=( (0 + 0) / 1 ) / 0.019
=0 / 0.019
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx  (OTCPK:VRCDF) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Verici Dx's Days Inventory for the six months ended in Jun. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Jun. 2023 )/Cost of Goods Sold (Q: Jun. 2023 )*Days in Period
=0/0.003*365 / 2
=0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Verici Dx's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jun. 2023 ) / Average Total Inventories (Q: Jun. 2023 )
=0.003 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verici Dx Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Verici Dx's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx (Verici Dx) Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (Verici Dx) Headlines

No Headlines